R
Rezera Inc.
Small molecule drug candidate to treat inflammatory diseases, as well as other drugs for neurodegenerative diseases and cancers
About Rezera Inc.
NodThera is a biotechnology company focused on developing innovative therapeutics targeting the NLRP3 inflammasome, a protein complex involved in the body's inflammatory response. The company operates in the pharmaceutical and healthcare market, serving patients suffering from chronic inflammatory diseases. NodThera's business model revolves around its proprietary drug discovery platform, which leverages advanced medicinal chemistry to create next-generation small molecule inhibitors. These inhibitors are designed for high potency, optimal pharmacokinetics (how the drug moves through the body), and effective tissue penetration. The company generates revenue through the development and potential commercialization of its drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies. NodThera's lead candidate, NT 0167, is currently in Phase 1 clinical trials, assessing its safety and efficacy. The company is also progressing a pipeline of other NLRP3 inhibitors, including those capable of crossing the blood-brain barrier to treat neurological conditions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Montrose, United Kingdom
- Employees
- 23
- Open positions
- 1
- Dealroom signal
- 69.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Neurology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, uk is8 life sciences, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Oct 2021 | $0 | — | Undisclosed | ↗ |
| SERIES BOther financing | Jun 2020 | $59M | $165M | Cowen Group · Epidarex Capital · F-Prime · Sanofi Ventures | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Rezera Inc. is 3.7K monthly website visits, up 306.6% over the last three months. Rezera Inc.'s team grew 4.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
5AM Ventures
Sofinnova Partners
Epidarex Capital
F-Prime
Cowen Group
Sanofi Ventures
Novo Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Rezera Inc. on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Rezera Inc.’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.